SCHEMBL30126587

SCHEMBL30126587

CC(C)(C)OC(=O)Nc1ccc2cnsc2c1F

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.39
PSMB8 P28062 1/20 0.37
METAP1 P53582 1/20 0.37
KCNQ4 P56696 1/20 0.36
KCNQ5 Q9NR82 1/20 0.36
SLC22A12 Q96S37 3/20 0.35
LCK P06239 2/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
SYK P43405 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAP2K1 Q02750 1/20 0.35
BRAF P15056 1/20 0.35
NAMPT P43490 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28707071 0.72 CYP17A1 (0.43) CYP17A1METAP1KCNQ4KCNQ5RXFP1
SCHEMBL10187654 0.72 CYP17A1 (0.43) CYP17A1METAP1KCNQ4KCNQ5LCK
SCHEMBL18180255 0.71 NPC1 (0.39) CYP17A1METAP1LCKBRAFLMNA
SCHEMBL24427976 0.71 CYP17A1 (0.42) CYP17A1METAP1KCNQ4KCNQ5RXFP1
SCHEMBL30739735 0.71 CYP17A1 (0.44) CYP17A1METAP1KCNQ4KCNQ5BRAF
SCHEMBL7008829 0.71 CYP17A1 (0.44) CYP17A1PSMB8METAP1KCNQ4KCNQ5
SCHEMBL29021810 0.70 CYP17A1 (0.44) CYP17A1KCNQ4KCNQ5RXFP1LMNA
SCHEMBL29069807 0.70 CYP17A1 (0.41) CYP17A1PSMB8METAP1KCNQ4KCNQ5
SCHEMBL31009176 0.70 CYP17A1 (0.44) CYP17A1KCNQ4KCNQ5RXFP1LMNA
SCHEMBL29932426 0.70 CYP17A1 (0.44) CYP17A1KCNQ4KCNQ5RXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024249642-A1 EGFR INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2024-12-05 WO disclosed
WO-2022266458-A1 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed